LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
Discover why LeMaitre's expansion in the peripheral vascular disease market and strong dividend growth make it an appealing ...
LeMaitre Vascular Third Quarter 2024 Earnings: Beats Expectations
Third Quarter 2024 Results Key Financial Results Revenue: US$54.8m (up 16% from ...
LeMaitre to Participate at Upcoming Investor Conferences in November
BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:LMAT) announced today that management will be participating in ...
Lemaitre Vascular: Strong Financial Performance and Positive Outlook Drive OUTPERFORM Rating
In a report released today, Michael Petusky from Barrington maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report), with a ...
In-Depth Examination Of 4 Analyst Recommendations For LeMaitre Vascular
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $95.25, a high ...
Lemaitre Vascular: Strong Buy Rating Supported by Robust Financials and Strategic Growth Initiatives
Lemaitre Vascular (LMAT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel ...
LeMaitre: Q3 Earnings Snapshot
For the current quarter ending in December, LeMaitre said it expects revenue in the range of $54.9 million to $56.9 million. The company expects full-year earnings to be $1.91 to $1.96 per share, with ...
LeMaitre Vascular Q3 2024 Earnings Preview
LeMaitre Vascular (NASDAQ:LMAT) is scheduled to announce Q3 earnings results on Thursday, October 31st, after market close. The consensus EPS Estimate is $0.43 (+30.3% Y/Y) and the consensus Revenue ...